1Velasco R, Bruna J. Chemotherapy-induced peripheral neuropathy : an unresolved issue[ J]. Neurologia, 2010,25 (2) : 116-131.
2Seuteri A, Galimberti A. Role of MAPKs in platinum-induced neuronal apoptosis[J]. Neurotoxieology, 2009,30(2) : 312-319.
3Tofthagen C, McAllister RD, McMillan SC. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin[J]. Clin J Oncol Nuts,2011,15(2) : 182-188.
4Tofthagen C, Overcash J, Kip K. Falls in persons with chemotherapy-induced peripheral neuropathy[J]. Support Care Cancer, 2011 (5):10.
5Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature[ J]. Blood, 2008,112(5) : 1593-1599.
6Wolf S, Barton D. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies [ J ]. Eur J Cancer, 2008,44 (11) :1507-1515.
7Cavaletti G, Marmiroli P. The role of growth factors in the prevention and treatment of chemotherapy-induced peripheral neurotoxicity[J] .Curr Drug Saf,2006,1(1) :35-42.
8Engle DB,Belisle JA. Effect of acetyl-l-camitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin. [J]. Gynecol Oncol, 2009,112: 631-636.
9Kouvaris JR, Kotdoulias VE, Vlahos LJ. Amifostine : the first selective-target and broad-spectrum radioprotector [J]. Oncologist, 2007,12(6) :738-747.
